Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
According to Ipsen, NAPOLI 3 is the first positive Phase III trial in mPDAC to show better OS compared to the current standard-of-care regimen, which consists of nab-paclitaxel and gemcitabine
This leads to optimized treatment plans, a better understanding of patient responses, and overall improving the efficacy of GLP-1 drugs
The comparison between retatrutide and tirzepatide reveals this as more than a marginal improvement
IGF-1 is the slower, integrated readout
US$ 28.84
US$ 27.71
US$ 29.69
US$ 25.54
US$ 26.52
